TRPV6 and ovarian neoplasm: SOR-C13, a TRPV6 calcium channel inhibitor, significantly reduces ovarian tumor growth in vivo and thus enters a phase I human clinical trial in patients with advanced ovarian cancers overexpressing TRPV6 138.